Citations

Showing 10 of 108152 citations.

We (Now) Know What We Are, But Not What We May Be 1
Taner, Timuçin , Heimbach, Julie K.

Mayo Clinic

Transplantation | July 24, 2019 | Volume: 103 | Issue: 10 | Pages: 1978-1979

10.1097/tp.0000000000002644 | PMID 31568230 Get It

ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma
Johnston, Sandra K. , Whitmire, Paula , Kumthekar, Priya , Porter, Alyx B. , Raghunand, Natarajan , Gonzalez‐Cuyar, Luis F. , Mrugała, Maciej M. , Hu, Leland , Wang, Lei , Egan, Kathleen M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Massey, Susan Christine , Hawkins‐Daarud, Andrea , Jackson, Pamela , Sarkaria, Jann N. , Gatenby, Robert A.

Mayo Clinic

American Journal of Clinical Oncology | July 24, 2019 | Volume: 42 | Issue: 8 | Pages: 655-661

10.1097/coc.0000000000000564 | PMID 31343422 Get It

Although glioblastoma (GBM) is a fatal primary brain cancer with short median survival of 15 months, a small number of patients survive >5 years after diagnosis; they are known as extreme survivors (ES). Because of their rarity, very little is known about what differentiates these outliers from other patients with GBM. For the purpose of identifying unknown drivers of extreme survivorship in GBM, the ENDURES consortium (ENvironmental Dynamics Underlying Responsive Extreme Survivors of GBM) was developed. This consortium is a multicenter collaborative network of investigators focused on the integration of multiple types of clinical data and the creation of patient-specific models of tumor growth informed by radiographic and histologic parameters. Leveraging our combined resources, the goals of the ENDURES consortium are 2-fold: (1) to build a curated, searchable, multilayered repository housing clinical and outcome data on a large cohort of ES patients with GBM; and (2) to leverage the ENDURES repository for new insights into tumor behavior and novel targets for prolonging survival for all patients with GBM. In this article, the authors review the available literature and discuss what is already known about ES. The authors then describe the creation of their consortium and some preliminary results.
In Remembrance of Hiroshi Takeshita, MD, Pioneering Neuroanesthesiologist
Lanier, William L. , Ereth, Mark H. , Seo, Katsuhiro

Mayo Clinic

Journal of Neurosurgical Anesthesiology | July 24, 2019 | Volume: 31 | Issue: 4 | Pages: 364-365

10.1097/ana.0000000000000626 Get It

Preoperative Dehydration does not Increase the Risk of Complications Following Elective Lumbar Surgery
Renfree, Sean P. , Chung, Andrew S. , Waldrop, Robert, Crandall, Dennis G. , Chang, Michael S. , Crandall, Dennis, Renfree, Sean , Chung, Andrew

Mayo Clinic

Spine | July 24, 2019 | Volume: 44 | Issue: 22 | Pages: E1336-E1341

10.1097/brs.0000000000003149 | PMID 31689256 Get It

Study Design. A retrospective cohort study. Objective. The aim of this study was to evaluate the effect of preoperative dehydration on hospital length of stay (LOS), rates of 30-day postoperative complications, related reoperations, and readmissions. Summary of Background Data. Preoperative dehydration has long been associated with postoperative infection, deep vein thrombosis (DVT), acute renal failure, and an increased hospital LOS. To our knowledge, the effect of preoperative dehydration on complication rates for patients undergoing elective lumbar spine surgery has not been well described. Methods. An analysis of American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) data from 2006 to 2013 was performed. Patients undergoing elective lumbar procedures were identified and exclusion criteria eliminated patients who underwent any emergency procedures, infections, tumor cases, or revision surgeries. Patient dehydration was defined as preoperative blood urea nitrogen/creatinine (BUN/Cr) ratio greater than 20. Results. Patients (4698; 34.5%) with preoperative dehydration based on BUN/Cr ratio were identified. Univariate analysis was suggestive of an association between preoperative dehydration and an increased risk of DVT (1.1% compared with 0.6%; P = 0.002), urinary tract infection (2.5% compared with 1.6%; P < 0.001), and need for transfusion postoperatively (17.6% compared with 14.4%; P < 0.001). However, on the basis of multivariate regression, no significant association between dehydration and increased odds of aforementioned outcomes was identified. Conclusion. Preoperative dehydration does not appear to negatively affect perioperative outcomes or readmission in patients undergoing elective lumbar spine surgery. Level of Evidence: 3
Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury
Joannidis, Michael , Shi, Jing , Chawla, Lakhmir S. , Kellum, John A. , Kellum, John A , Forni, Lui G. , Haase, Michael , Koyner, Jay L. , Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | July 24, 2019 | Volume: 47 | Issue: 10 | Pages: e820-e826

10.1097/ccm.0000000000003907 | PMID 31343478 Get It

Objectives: Decreased urine output and/or increased serum creatinine may herald the development of acute kidney injury or reflect normal physiology. In this secondary analysis of the Sapphire study, we examined biomarkers of cell cycle arrest in the settings of oliguria and/or azotemia to improve risk assessment when used with conventional indices in predicting severe acute kidney injury (Kidney Disease: Improving Global Outcomes 3 defined by the need for renal replacement therapy or changes in urine output, serum creatinine or both) or death. Design: Prospective, international, Sapphire study. Setting: Academic Medical Center. Patients: Patients without acute kidney injury Kidney Disease: Improving Global Outcomes stage 2 or 3. Interventions: None. Measurements and Main Results: The primary endpoint being development of severe acute kidney injury or death within 1 week. Secondary analysis examined the relationship between tissue inhibitor of metalloproteinases-2 ([TIMP-2]) and insulin growth factor binding protein 7 ([IGFBP7]) and 9-month death or dialysis conditioned on progression to stage 2–3 acute kidney injury within 1 week. Seventy-nine patients reached the primary endpoint and were more likely to be surgical, with higher nonrenal Acute Physiology and Chronic Health Evaluation III scores and more chronic kidney disease. Stage 1 urine output, serum creatinine, and urinary [TIMP-2]•[IGFBP7] greater than 2.0 were all predictive of progression to the primary endpoint independent from nonrenal Acute Physiology and Chronic Health Evaluation III score. Combinations of predictors increased the hazard ratios considerably (from 2.17 to 4.14 to 10.05, respectively). In the presence of acute kidney injury (stage 1), [TIMP-2]•[IGFBP7] greater than 2.0 leads to an increased risk of death or dialysis at 9 months even in the absence of progression of acute kidney injury (stage 2–3) within 7 days. Conclusions: Cell cycle arrest biomarkers, TIMP-2 and IGFBP7, improve risk stratification for severe outcomes in patients with stage 1 acute kidney injury by urine output, serum creatinine or both, with risk increasing with each acute kidney injury indicator. Longer term outcomes demonstrate that the associated risks of a [TIMP-2]•[IGFBP7] greater than 2.0 is equivalent to acute kidney injury progression even where no progression from stage 1 acute kidney injury is observed.
Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie’s Disease in an Era of Effective Clinical Treatment
Wymer, Kevin , Köhler, Tobias , Trost, Landon

Mayo Clinic

The Journal of Sexual Medicine | July 24, 2019 | Volume: 16 | Issue: 9 | Pages: 1421-1432

10.1016/j.jsxm.2019.06.010 | PMID 31351851 Get It

ABSTRACT Background Traditionally, surgery has been considered the gold standard treatment for Peyronie’s disease (PD). Less-invasive alternatives, such as collagenase Clostridium histolyticum (CCH) and traction therapy, have been proposed and proven effective. Aim To compare cost-effectiveness of management options for PD. Methods A Markov analytic model was created to compare the cost-effectiveness of treatment with a novel traction device, RestoreX (RXPTT), vs CCH vs surgery. Outcomes were derived from single-institution, prospective data of 63 men treated with RXPTT, 115 with CCH, and 23 with plication or incision and grafting. Costs were based on 2017 Medicare reimbursement and utility values from the literature. Main Outcome Measures Model outcomes included complications for each treatment arm, as well as the probability of success, which was defined as ≥20% improvement in curvature. Univariable and multivariable sensitivity analyses were performed to test the robustness of the model. Results Overall success rates were 96% (surgery), 66% (CCH), and 48% (RXPTT). At 10 years after treatment, RXPTT was the most cost-effective, with mean costs per patient of $883 (RXPTT), $11,419 (surgery), and $33,628 (CCH). CCH and surgery both resulted in a gain of quality adjusted life years (QALYs) relative to RXPTT (9.44 and 9.36 vs 9.27, respectively). Sensitivity analysis demonstrated greater cost-effectiveness for surgery if lower (≤46%) rates of postoperative erectile dysfunction or length loss (≤3%). CCH became more cost-effective at lower costs (≤$16,726) or higher success rates (≥76%). On multivariable sensitivity analysis at a willingness to pay threshold of $100,000/QALY, the most cost-effective strategy was RXPTT in 49%, surgery in 48%, and CCH in 3% of simulations. At a willingness to treat threshold of $150,000/QALY, the most cost-effective treatment option was RXPTT in 33%, surgery in 55%, and CCH in 12% of simulations. Clinical Implications In an era of value-based care, this model can guide cost-effective treatment selection on the basis of provider, patient, and payer characteristics. Strengths & Limitations The current study represents the first cost-effectiveness comparison of treatment modalities for PD and is strengthened by prospective data collection, large CCH and traction sample sizes, and robust sensitivity analyses. Consistent with cost-effective models, the model is limited by assumptions and may not apply to all scenarios. Conclusions RXPTT represents a more cost-effective method for achieving ≥20% curvature improvement compared with surgery or CCH. Depending on treatment goals, rate of surgical complications, and willingness to pay threshold, surgery and CCH may become more cost-effective in select scenarios.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Tam, Constantine S. , Opat, Stephen , Burger, Jan A. , Cull, Gavin , Gottlieb, David , Johnston, Patrick B. , Marlton, Paula , Seymour, John F. , Simpson, David , Tedeschi, Alessandra , Elstrom, Rebecca, Yu, Yiling , Tang, Zhiyu , Han, Lynn , Huang, Jane , Novotny, William , Wang, Lai, Roberts, Andrew W. , Trotman, Judith , Burger, Jan A , Seymour, John F , Simpson, David , Roberts, Andrew W , Tam, Constantine S , Opat, Stephen , Harrup, Rosemary Anne , Muñoz, Javier

Mayo Clinic

Blood | July 24, 2019 | Volume: 134 | Issue: 11 | Pages: 851-859

10.1182/blood.2019001160 | PMID 31340982 Get It

Abstract Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily or 160 mg twice daily. Part 2 (expansion) consisted of disease-specific cohorts, including treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The primary end points were safety and tolerability, and definition of the maximum tolerated dose (part 1). Additional end points included pharmacokinetics/pharmacodynamics and preliminary efficacy. Reported herein are results from 144 patients enrolled in the dose-finding and CLL/SLL cohorts. No dose-limiting toxicities occurred in dose escalation. Median BTK occupancy in peripheral blood mononuclear cells was &gt;95% at all doses. Sustained complete (&gt;95%) BTK occupancy in lymph node biopsy specimens was more frequent with 160 mg twice daily than 320 mg once daily (89% vs 50%; P = .0342). Consequently, 160 mg twice daily was selected for further investigation. With median follow-up of 13.7 months (range, 0.4-30.5 months), 89 CLL/SLL patients (94.7%) remain on study. Most toxicities were grade 1/2; neutropenia was the only grade 3/4 toxicity observed in &gt;2 patients. One patient experienced a grade 3 subcutaneous hemorrhage. Among 78 efficacy-evaluable CLL/SLL patients, the overall response rate was 96.2% (95% confidence interval, 89.2-99.2). Estimated progression-free survival at 12 months was 100%. Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities. This trial was registered at www.clinicaltrials.gov as #NCT02343120.
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Widemann, Brigitte C. , Lu, Yao , Okuno, Scott H. , Meyer, Christian F. , Chugh, Rashmi , Milhem, Mohammed , Hirbe, Angela C. , Kim, AeRang , Turpin, Brian , Pressey, Joseph G. , Jayaprakash, Nalini, Helman, Lee J. , Onwudiwe, Ndidi, Cichowski, Karen , Perentesis, John P. , Okuno, Scott , Chugh, Rashmi , Milhem, Mohammed M , Hirbe, Angela C , Kim, AeRang , Pressey, Joseph G , Reinke, Denise K. , Coté, Gregory M. , Dombi, Eva , Cichowski, Karen M.

Mayo Clinic

Sarcoma | July 24, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-8

10.1155/2019/7656747 | PMID 31427883 Get It

Purpose. There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease progression. We conducted a phase II study for patients (pts) with refractory MPNST combining everolimus (10 mg PO once daily) with bevacizumab (10 mg/kg IV every 2 weeks) to determine the clinical benefit rate (CBR) (complete response, partial response (PR), or stable disease (SD) ≥ 4 months). Patients and Methods. Patients ≥18 years old with chemotherapy refractory sporadic or NF1 MPNST were eligible. Tumor response was assessed after every 2 cycles (the WHO criteria). A two-stage design targeting a 25% CBR was used: if ≥ 1/15 pts in stage 1 responded, enrollment would be expanded by 10 pts, and if ≥ 4/25 patients had clinical benefit, the combination would be considered active. Results. Twenty-five pts, 17 with NF1 and 8 with sporadic MPNST, enrolled. One of 15 pts in stage 1 had clinical benefit. Of 10 additional pts enrolled, 2 had clinical benefit. The median number of completed cycles was 3 (range 1–16). Adverse events were similar to those known for this combination. Conclusion. With a CBR of 12% (3/25), the combination of everolimus and bevacizumab did not reach the study’s target response rate and is not considered active in refractory MPNST.
Molecular profiling of long-term IDH-wildtype glioblastoma survivors
Yang, Jie , Decker, Paul A. , Kollmeyer, Thomas M. , Kosel, Matthew , Mladek, Ann C. , Caron, Alissa, Kitange, Gaspar J. , Sicotte, Hugues , Youland, Ryan S. , Voss, Jesse S. , Kolsky, K. L., Meyer, Fredric B. , Parney, Ian, Kipp, Benjamin R. , Sulman, Erik P. , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Burgenske, Danielle M. , Caron, Alissa A, Gupta, Shiv K. , Fritcher, Emily G. Barr , Kolsky, Kathryn L, Parney, Ian J, Kollmeyer, Thomas , Sulman, Erik P , Mladek, Ann C , Decker, Paul A. , Vaubel, Rachael A. , Remonde, Dioval , Ida, Cristiane M. , Lachance, Daniel Honore , Giannini, Caterina , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1458-1469

10.1093/neuonc/noz129 | PMID 31346613 Get It

AbstractBackgroundGlioblastoma (GBM) represents an aggressive cancer type with a median survival of only 14 months. With fewer than 5% of patients surviving 5 years, comprehensive profiling of these rare patients could elucidate prognostic biomarkers that may confer better patient outcomes. We utilized multiple molecular approaches to characterize the largest patient cohort of isocitrate dehydrogenase (IDH)–wildtype GBM long-term survivors (LTS) to date.MethodsRetrospective analysis was performed on 49 archived formalin-fixed paraffin embedded tumor specimens from patients diagnosed with GBM at the Mayo Clinic between December 1995 and September 2013. These patient samples were subdivided into 2 groups based on survival (12 LTS, 37 short-term survivors [STS]) and subsequently examined by mutation sequencing, copy number analysis, methylation profiling, and gene expression.ResultsOf the 49 patients analyzed in this study, LTS were younger at diagnosis (P = 0.016), more likely to be female (P = 0.048), and MGMT promoter methylated (UniD, P = 0.01). IDH-wildtype STS and LTS demonstrated classic GBM mutations and copy number changes. Pathway analysis of differentially expressed genes showed LTS enrichment for sphingomyelin metabolism, which has been linked to decreased GBM growth, invasion, and angiogenesis. STS were enriched for DNA repair and cell cycle control networks.ConclusionsWhile our findings largely report remarkable similarity between these LTS and more typical STS, unique attributes were observed in regard to altered gene expression and pathway enrichment. These attributes may be valuable prognostic markers and are worth further examination. Importantly, this study also underscores the limitations of existing biomarkers and classification methods in predicting patient prognosis.
Carotid Artery Injury during Transsphenoidal Pituitary Surgery: Lessons from a 15-Year Modern Microsurgery Cohort
Meyer, Jenna , Perry, Avital , Graffeo, Christopher S. , Marcellino, Chris , Burrows, Anthony M. , Driscoll, Colin L. W., Meyer, Fredric B. , Carlstrom, Lucas P. , Marcellino, Christopher R, Burrows, Anthony, Marcellino, Christopher , Bancos, Irina

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | July 24, 2019 | Volume: 81 | Issue: 05 | Pages: 594-602

10.1055/s-0039-1692484 | PMID 33134028 Get It

Background Internal carotid artery (ICA) injury is a rare but potentially catastrophic complication of transsphenoidal resection (TSR) of pituitary tumors, potentially resulting in a host of deficits due to the risk of hemorrhage, ischemia, or even death. The endoscopic endonasal approach (EEA) has gained considerable popularity in the modern era, with few busy neurosurgeons remaining committed to practicing transnasal pituitary microsurgery. Our objective was therefore to characterize the overall incidence of ICA injury in a large, longitudinal, single-surgeon microscopic TSR series conducted during the modern EEA era. Methods Retrospective case series. Results Overall TSR volume by the senior author (F.B.M.) was 817 pituitary tumors during the study period, 2002 to 2017. Within that cohort, two instances of ICA injury were identified (0.2%), including one each with Cushing's disease and acromegaly, both of whom ultimately recovered without residual neurologic deficit. No pediatric injuries were identified. Conclusion Vascular injury is an exceedingly rare complication of transsphenoidal pituitary surgery. Adjuncts to prevent this complication include careful review of the coronal magnetic resonance imaging, identification of the midline, as needed use of the Doppler, and initial caudal opening of the sellar dura. Although potentially disastrous, good neurologic outcomes may be obtained, with immediate judicious packing followed by immediate digital subtraction angiography to assess vessel patency and secondary complications such as pseudoaneurysm.